Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SOPH Stock Forecast 2025-2026
$3.04
Current Price
$206.14M
Market Cap
Buy 5
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to SOPH Price Targets
+261.8%
To High Target of $11.00
+97.4%
To Median Target of $6.00
+64.5%
To Low Target of $5.00
SOPH Price Momentum
+5.9%
1 Week Change
+5.6%
1 Month Change
-35.3%
1 Year Change
-1.0%
Year-to-Date Change
-39.8%
From 52W High of $5.05
+17.8%
From 52W Low of $2.58
📊 TOP ANALYST CALLS
Did SOPH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if SOPHiA GENETICS is one of their latest high-conviction picks.
Latest SOPH Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, SOPH has a bullish consensus with a median price target of $6.00 (ranging from $5.00 to $11.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $3.04, the median forecast implies a 97.4% upside. This outlook is supported by 5 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Rich Hilliker at Credit Suisse, suggesting a 64.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SOPH Analyst Ratings
5
Buy
1
Hold
0
Sell
SOPH Price Target Range
Low
$5.00
Average
$6.00
High
$11.00
Current: $3.04
Latest SOPH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SOPH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 18, 2024 | Craig-Hallum | Buy | Initiates | $11.00 | |
| Aug 7, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $7.00 |
| Jun 27, 2024 | Guggenheim | Subbu Nambi | Buy | Initiates | $6.00 |
| Mar 6, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $8.00 |
| Mar 6, 2024 | BTIG | Mark Massaro | Buy | Maintains | $8.00 |
| Jan 12, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $8.00 |
| Nov 29, 2023 | RBC Capital | Conor McNamara | Outperform | Initiates | $8.00 |
| May 10, 2023 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $10.00 |
| May 10, 2023 | Credit Suisse | Rich Hilliker | Neutral | Maintains | $5.00 |
| Mar 8, 2023 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $11.00 |
| Jan 3, 2023 | BTIG | Mark Massaro | Buy | Initiates | $6.00 |
| Nov 23, 2022 | Credit Suisse | Phil Winslow | Neutral | Initiates | $2.00 |
| Nov 9, 2022 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $12.00 |
| Aug 10, 2022 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $13.00 |
| May 11, 2022 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $14.00 |
| Mar 16, 2022 | Morgan Stanley | Overweight | Maintains | $17.00 | |
| Feb 15, 2022 | Morgan Stanley | Overweight | Maintains | $18.00 | |
| Aug 17, 2021 | Cowen & Co. | Outperform | Initiates | $0.00 | |
| Aug 17, 2021 | Morgan Stanley | Overweight | Initiates | $0.00 | |
| Aug 17, 2021 | JP Morgan | Overweight | Initiates | $0.00 |
Sophia Genetics SA (SOPH) Competitors
The following stocks are similar to SOPHiA GENETICS based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Sophia Genetics SA (SOPH) Financial Data
Sophia Genetics SA has a market capitalization of $206.14M with a P/E ratio of -3.2x. The company generates $67.17M in trailing twelve-month revenue with a -98.5% profit margin.
Revenue growth is +12.7% quarter-over-quarter, while maintaining an operating margin of -90.2% and return on equity of -60.8%.
Valuation Metrics
Market Cap
$206.14M
Enterprise Value
$156.72M
P/E Ratio
-3.2x
PEG Ratio
-3.8x
Price/Sales
3.1x
Growth & Margins
Revenue Growth (YoY)
+12.7%
Gross Margin
+68.7%
Operating Margin
-90.2%
Net Margin
-98.5%
EPS Growth
+12.7%
Financial Health
Cash/Price Ratio
+33.8%
Current Ratio
3.1x
Debt/Equity
35.2x
ROE
-60.8%
ROA
-24.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Sophia Genetics SA (SOPH) Business Model
About Sophia Genetics SA
What They Do
Enables data-driven medicine through AI and analytics.
Business Model
The company generates revenue by providing healthcare institutions with advanced data interpretation solutions that leverage artificial intelligence and data analytics. By offering a platform that integrates various types of medical data, Sophia Genetics empowers healthcare providers to develop personalized treatment plans, thus improving clinical diagnosis across multiple medical sectors.
Additional Information
Founded in 2011, Sophia Genetics focuses on enhancing patient outcomes through data standardization and accessibility. It operates in oncology, cardiology, and rare genetic disorders, contributing significantly to the field of precision medicine and innovation in healthcare diagnostics.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
423
CEO
Dr. Jurgi Camblong M.B.A., Ph.D.
Country
Switzerland
IPO Year
2021
Website
www.sophiagenetics.comSophia Genetics SA (SOPH) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today?
Tempus AI surges 12.5% on new AI tools, a $200M AstraZeneca deal, and clinical data expansion- but is it time to buy?
Jun 09, 2025
By Urmimala Biswas
Analyst Blog
Latest News
Quick Summary
SOPHiA GENETICS SA (NASDAQ:SOPH) will hold its Q1 2025 Earnings Conference Call on May 6, 2025, at 8:00 AM ET, featuring key company executives and analysts from various firms.
Why It Matters
SOPHiA GENETICS' earnings call signals key financial insights and strategic updates, impacting stock performance and investor sentiment regarding the company's growth prospects.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
SOPHiA GENETICS reported Q1 2025 revenue of $17.8M, up 13% YoY. Gross margin improved to 68.7%. Net loss increased to $17.4M, while adjusted EBITDA loss decreased to $9.8M. Full-year guidance remains unchanged.
Why It Matters
SOPHiA GENETICS shows solid revenue growth and improving gross margins, indicating strong market demand. However, increasing net losses may raise concerns about profitability and cash flow.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
SOPHiA GENETICS SA reported a quarterly loss of $0.26 per share, exceeding the Zacks estimate of $0.21 and compared to a loss of $0.21 per share a year earlier.
Why It Matters
SOPHiA GENETICS' larger-than-expected quarterly loss may signal ongoing financial struggles, potentially affecting investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
SOPHiA GENETICS expands its collaboration with AstraZeneca to globally deploy MSK-ACCESS® powered by SOPHiA DDM™, reaching 30 clinical institutions in 2025.
Why It Matters
The expansion of SOPHiA GENETICS' collaboration with AstraZeneca enhances market reach and innovation, potentially increasing revenue, market share, and investor confidence in both companies.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
SOPHiA GENETICS will release Q1 2025 financial results on May 6, 2025, before the market opens, followed by a conference call at 8:00 a.m. to discuss results and outlook.
Why It Matters
SOPHiA GENETICS' upcoming Q1 2025 financial results and conference call may influence stock performance, providing insight into its growth and business direction.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
A new partnership combines AI-driven analytics with clinical trial solutions to help biopharma companies speed up drug development and deliver targeted therapies more efficiently.
Why It Matters
The partnership enhances drug development efficiency in biopharma, potentially increasing the success rates of new therapies and driving growth in the sector, influencing stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SOPH Stock
What is Sophia Genetics SA's (SOPH) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Sophia Genetics SA (SOPH) has a median price target of $6.00. The highest price target is $11.00 and the lowest is $5.00.
Is SOPH stock a good investment in 2025?
According to current analyst ratings, SOPH has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SOPH stock?
Wall Street analysts predict SOPH stock could reach $6.00 in the next 12 months. This represents a 97.4% increase from the current price of $3.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sophia Genetics SA's business model?
The company generates revenue by providing healthcare institutions with advanced data interpretation solutions that leverage artificial intelligence and data analytics. By offering a platform that integrates various types of medical data, Sophia Genetics empowers healthcare providers to develop personalized treatment plans, thus improving clinical diagnosis across multiple medical sectors.
What is the highest forecasted price for SOPH Sophia Genetics SA?
Price targets from Wall Street analysts for SOPH are not currently available. The stock is trading at $3.04.
What is the lowest forecasted price for SOPH Sophia Genetics SA?
The lowest price target for SOPH is $5.00 from Rich Hilliker at Credit Suisse, which represents a 64.5% increase from the current price of $3.04.
What is the overall SOPH consensus from analysts for Sophia Genetics SA?
The overall analyst consensus for SOPH is bullish. Out of 7 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are SOPH stock price projections?
Stock price projections, including those for Sophia Genetics SA, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 12:03 PM UTC